PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.35%
G&A change of 60.35% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
117.22%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
89.95%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
89.95%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
-4.24%
Both companies reducing interest expense. Martin Whitman would check industry trends.
100.53%
D&A growth above 1.5x TRVN's 6.74%. Michael Burry would check for excessive investment.
79.29%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-95.43%
Operating income decline while TRVN shows 14.24% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-104.55%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-100.00%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.40%
Both companies reducing tax expense. Martin Whitman would check patterns.
-134.36%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-134.21%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-134.21%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.